By Adriano Marchese
Knight Therapeutics has agreed to acquire generics and specialty branded pharmaceutical company Paladin Pharma for 120 million Canadian dollars ($83.1 million).
The specialty pharmaceutical company said Tuesday it has entered into a definitive asset-purchase agreement with Endo Operations and Paladin Pharma for the acquisition. The upfront payment in cash will also include inventory with a value of C$20 million.
Knight said that it may also pay up to another US$15 million for reaching certain milestones.
Knight Chief Executive Samira Sakhia said the synergistic transaction adds critical mass and significantly increases the size of its Canadian business as well as in Latin America.
"The acquisition adds a portfolio of stable cash flow generating pharmaceuticals that will help fund our growth in Canada and Latin America," Sakhia said.
The transaction is expected to close sometime mid-year.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 11, 2025 08:25 ET (12:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.